Glucose Laboratoire Aguettant (Glucose Monohydrate)

Glucose Laboratoire Aguettant is used in several clinical situations where rapid provision of carbohydrate energy or fluid balance is needed.

• Treatment of acute hypoglycemia when oral glucose is not feasible.
• As part of fluid replacement therapy in patients requiring isotonic solutions.
• Component of parenteral nutrition regimens to supply calories.
• Support during surgical procedures to maintain blood glucose levels.
• Management of electrolyte imbalances when combined with appropriate salts.

When administered intravenously, Glucose Laboratoire Aguettant may be associated with a range of observed effects, most of which are related to the infusion of a carbohydrate solution and the accompanying osmotic load.

Common

• Transient increase in blood glucose concentration.
• Mild hyperosmolarity leading to temporary thirst.
• Local irritation at the injection site.
• Nausea or mild gastrointestinal discomfort.
• Temporary rise in serum insulin levels.

Serious

• Severe hyperglycemia, especially in patients with diabetes mellitus.
• Fluid overload resulting in pulmonary edema.
• Electrolyte disturbances such as hyponatremia.

Clinicians should observe specific precautions when prescribing or administering Glucose Laboratoire Aguettant to minimize risks and ensure patient safety.

• Verify blood glucose levels before and during infusion.
• Adjust infusion rate in patients with impaired renal or cardiac function.
• Use aseptic technique to prevent contamination of the sterile solution.
• Monitor fluid balance to avoid overload, especially in elderly or critically ill patients.
• Consider contraindications in individuals with known hypersensitivity to glucose solutions.
• Avoid rapid bolus administration unless clinically indicated.
• Store according to manufacturer guidelines, protecting from light and extreme temperatures.

Glucose Laboratoire Aguettant can interact with other medications or clinical conditions, requiring careful assessment to avoid adverse outcomes.

Avoid

• Concurrent high‑dose insulin therapy without glucose monitoring.
• Co‑administration with hypertonic saline solutions that may exacerbate hyperosmolar states.

Use with caution

• Diabetic patients receiving oral hypoglycemic agents; monitor glucose closely.
• Patients on diuretics or cardiac drugs, as fluid shifts may affect drug distribution.
• Use with caution in renal impairment where glucose clearance is reduced.
• Concurrent administration with potassium‑containing solutions; monitor electrolyte levels.